SPAGO — Spago Nanomedical AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK91.30m
- SEK61.63m
- SEK0.44m
Annual income statement for Spago Nanomedical AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.66 | 1.05 | 1.2 | 1.91 | 0.437 |
| Cost of Revenue | |||||
| Gross Profit | 4.92 | 4.75 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 39.9 | 40.5 | 44.3 | 35.6 | 27.4 |
| Operating Profit | -39.2 | -39.5 | -43.1 | -33.7 | -26.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -39.1 | -39.2 | -42.2 | -32.5 | -26.6 |
| Net Income After Taxes | -39.1 | -39.2 | -42.2 | -32.5 | -26.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -39.1 | -39.2 | -42.2 | -32.5 | -26.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -39.1 | -39.2 | -42.2 | -32.5 | -26.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.662 | -0.416 | -0.305 | -0.078 | -0.05 |
| Dividends per Share |